

Company registration number: 748703

Methapharm Limited

Unaudited abridged financial statements

for the financial year ended 30 September 2025

Methapharm Limited

Contents

	Page
Directors responsibilities statement	1
Statement of financial position	2 - 3
Notes to the abridged financial statements	4 - 6

Methapharm Limited

Directors responsibilities statement

These abridged financial statements have been extracted, pursuant to section 353 of the Companies Act 2014, from the statutory financial statements prepared under section 290 of that Act. The following is the Directors Responsibilities Statement accompanying those financial statements.

The directors are responsible for preparing the directors report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the directors to prepare financial statements for each financial year. Under the law, the directors have elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, which was issued by the Financial Reporting Council. Under company law, the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the directors are required to:

- select suitable accounting policies and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The directors are responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and directors report comply with the Companies Act 2014. They are also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Robert Craig Baxter
Director

Christopher Haynes Calenti
Director

Date: 24 February 2026

Methapharm Limited

**Statement of financial position
As at 30 September 2025**

	Note	30 September 2025		30 September 2024	
		€	€	€	€
Current assets					
Debtors	5	200,105		75,294	
		<u>200,105</u>		<u>75,294</u>	
Creditors: amounts falling due within one year					
	6	(197,554)		(77,485)	
			2,551		(2,191)
Net current assets/(liabilities)			<u>2,551</u>		<u>(2,191)</u>
Total assets less current liabilities			2,551		(2,191)
			<u>2,551</u>		<u>(2,191)</u>
Net assets/(liabilities)			<u>2,551</u>		<u>(2,191)</u>
Capital and reserves					
Called up share capital presented as equity	7		100		100
Profit and loss account			2,451		(2,291)
			<u>2,551</u>		<u>(2,191)</u>
Shareholders funds/(deficit)			<u>2,551</u>		<u>(2,191)</u>

We, as directors of Methapharm Limited state that:

- the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014;
- the company is availing itself of the exemption on the grounds that the conditions specified in section 358 of the Companies Act 2014 are satisfied;
- the shareholders of the company have not served a notice on the company under section 334(1) of the Companies Act 2014 in accordance with section 334(2);
- We acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of Companies Act 2014 relating to financial statements so far as they are applicable to the company; and
- the company has relied on the specified exemption contained in section 352 of the Companies Act 2014; has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 of the Companies Act 2014.

The notes on pages 4 to 6 form part of these abridged financial statements.

Methapharm Limited

**Statement of financial position (continued)
As at 30 September 2025**

These financial statements were approved by the board of directors and signed on behalf of the board by:

Robert Craig Baxter
Director

Christopher Haynes Calenti
Director

Date: 24 February 2026

The notes on pages 4 to 6 form part of these abridged financial statements.

Methapharm Limited

Notes to the abridged financial statements Financial year ended 30 September 2025

1. General information

The company is a private company limited by shares (registered under Part 2 of the Companies Act 2014), incorporated and registered in Ireland (CRO number 748703). The address of the registered office is The Black Church, St. Mary's Place, Dublin 7. The nature of the company's operations and its principal activities are set out in the Directors' Report.

2. Accounting policies and measurement bases

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention modified to include certain items at fair value. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 (the Act) and FRS 102 The Financial Reporting Standard applicable in the UK and Republic of Ireland issued by the Financial Reporting Council. The company qualifies as a small company for the year, as defined by section 280A of the Act, in respect of the financial period, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Act and Section 1A of FRS 102.

The financial statements are prepared in Euro, which is the functional currency of the entity.

Turnover

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax.

Taxation

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively.

Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.

Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

Methapharm Limited

Notes to the abridged financial statements (continued) Financial year ended 30 September 2025

Financial instruments

Ordinary share capital

The ordinary share capital of the company is presented as equity.

Cash and cash equivalents

Cash consists of cash on hand and demand deposits. Cash equivalents consist of short term highly liquid investments that are readily convertible to known amounts of cash that are subject to an insignificant risk of change in value.

Other financial assets

Other financial assets including trade debtors arising from goods sold to customers on short-term credit, are initially measured at the undiscounted amount of cash receivable from that debtor, which is normally the invoice price. If payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate, this constitutes a financing transaction, and the financial liability is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Subsequently, other financial assets are measured at amortised cost less impairment, where there is objective evidence of impairment.

3. Staff costs

The average number of persons employed by the company during the financial year, including the directors was 3 (2024: 3).

The aggregate payroll costs (excluding directors remuneration) incurred during the financial year were:

	Year ended 30/09/25	Period ended 30/09/24
	€	€
Social insurance costs	1,242	103
	<u> </u>	<u> </u>

4. Directors remuneration

The directors aggregate remuneration was as follows:

	Year ended 30/09/25	Period ended 30/09/24
	€	€
Emoluments	14,000	1,167
	<u> </u>	<u> </u>

Methapharm Limited

Notes to the abridged financial statements (continued)
Financial year ended 30 September 2025

5. Debtors

	30/09/25	30/09/24
	€	€
Amounts owed by group undertakings	197,862	75,294
Other debtors	2,243	-
	<u>200,105</u>	<u>75,294</u>
	<u>200,105</u>	<u>75,294</u>

6. Creditors: amounts falling due within one year

	30/09/25	30/09/24
	€	€
Trade creditors	14,062	-
Amounts owed to group undertakings	178,871	73,216
Other creditors including tax and social insurance	1,621	1,269
Accruals	3,000	3,000
	<u>197,554</u>	<u>77,485</u>
	<u>197,554</u>	<u>77,485</u>

7. Called up share capital presented as equity

Issued, called up and fully paid

	30/09/25		30/09/24	
	Number	€	Number	€
Amounts presented in equity:				
Ordinary shares of €1.00 each	100	100	100	100
	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>
	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>

8. Approval of financial statements

The board of directors approved these abridged financial statements for issue on 24 February 2026.